Such efforts resulted in Gendicine (approved by state FDA in China) [106], the first gene therapy product with a combination of human wt p53 gene and adenovirus serotype-5 vector (Ad5) in 2003 for the treatment of head and neck cancer, and—later on—other types of cancer. The gene discussed is TP53; the disease is cancer.